Compounds of formula (I) are described in which Het is a five or six
membered heteroaromatic ring of the formula 1
in which one of R.sup.1 and R.sup.2 is optionally substituted heteroaryl
and the other is optionally substituted heteroaryl or optionally
substituted aryl; X.sup.1 is a bond, X.sup.3 and X.sup.4 are each
independently N or C and X.sup.2 and X.sup.5 are independently CH, N, NH,
O or S; or X.sup.3 and X.sup.4 are C, one of X.sup.1, X.sup.2 and X.sup.5
is N and the others are N or CH; but excluding compounds in which X.sup.1
is a bond, one of X.sup.2 and X.sup.5 is N and the other is NH and
X.sup.3 and X.sup.4 are both C; R.sup.3 represents a group
-L.sup.1-R.sup.6; R.sup.4 represents hydrogen, alkyl or hydroxyalkyl; or
R.sup.3 and R.sup.4, when attached to the same carbon atom, may form with
the said carbon atom a cycloalkyl, cycloalkenyl or heterocycloalkyl ring
or a group C.dbd.CH.sub.2; R.sup.5 represents hydrogen or alkyl; and m is
zero or an integer 1 or 2; and N-oxides thereof, and their prodrugs; and
pharmaceutically acceptable salts and solvates of compounds of formula
(I) and N-oxides thereof, and their prodrugs.
The compounds are TNF inhibitors and are useful as pharmaceuticals. 2
